← Leaderboards
John McLeod Griffiss
University Of California San Francisco
$31,289,846
Attributed
$31,289,846
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $12.5M · FY2005–18$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$31,289,846 · 7
By mechanism
N01$25,967,935 · 1
R01$5,308,029 · 3
P41$13,882 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Alma L Burlingame$22,822,480
- Marc Kopel Hellerstein$9,825,255
- Alan S Verkman$35,167,321
- Steven R Cummings$87,498,694
- Kathleen M Giacomini$35,943,104
Others in their field
Top investigators on “Infectious Disease Treatment”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$275,310,638
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$193,788,225
- Barbara Driver · Westat, Inc.$188,782,795
- Carol Nesel · Westat$188,148,170
- Daniel R Kuritzkes · Brigham And Women'S Hospital$143,516,856
Research focus
Infectious Disease TreatmentNovel TherapeuticsInvestigationPhase I Clinical TrialsCommunicable DiseasesClinical Trials UnitNeisseria GonorrhoeaeVaccinesGonorrheaInfectionImmunoglobulin GAffectResistancePreventSexually Transmitted DiseasesStructureLipooligosaccharideLifeBaseImmunogenicAntibodiesBinding (Molecular Function)OrganismStructural Biology
Grant awards (47)
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases$140,886
N01 · FY2018 · AI · contact PI
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases$312,440
N01 · FY2017 · AI · contact PI
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases$37,831
N01 · FY2016 · AI · contact PI
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases$20,375
N01 · FY2016 · AI · contact PI
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases$1,017,211
N01 · FY2015 · AI · contact PI
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases$2,409,113
N01 · FY2014 · AI · contact PI
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases$508,510
N01 · FY2014 · AI · contact PI
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases$304,384
N01 · FY2014 · AI · contact PI
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases$254,626
N01 · FY2014 · AI · contact PI
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases$222,974
N01 · FY2014 · AI · contact PI
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases$1,640,796
N01 · FY2013 · AI · contact PI
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases$607,020
N01 · FY2013 · AI · contact PI
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases$437,753
N01 · FY2013 · AI · contact PI
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases$5,651,802
N01 · FY2012 · AI · contact PI
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases$2,659,562
N01 · FY2012 · AI · contact PI
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases$2,592,417
N01 · FY2012 · AI · contact PI
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases$1,196,787
N01 · FY2012 · AI · contact PI
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases$200,000
N01 · FY2012 · AI · contact PI
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases$200,000
N01 · FY2012 · AI · contact PI
PHASE I CLINICAL TRIAL UNIT FOR THERAPEUTICS AGAINST INFECTIOUS DISEASES$2,000,000
N01 · FY2011 · AI · contact PI
PHASE I CLINICAL TRIAL UNIT FOR THERAPEUTICS AGAINST INFECTIOUS DISEASES$1,753,448
N01 · FY2011 · AI · contact PI
PHASE I CLINICAL TRIAL UNIT FOR THERAPEUTICS AGAINST INFECTIOUS DISEASES$1,500,000
N01 · FY2011 · AI · contact PI
Risk Factors and Susceptibility in Gonococcal Infection$387,984
R01 · FY2011 · AI · contact PI
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases$150,000
N01 · FY2011 · AI · contact PI
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases$150,000
N01 · FY2011 · AI · contact PI
Risk Factors and Susceptibility in Gonococcal Infection$391,892
R01 · FY2010 · AI · contact PI
Risk Factors and Susceptibility in Gonococcal Infection$184,066
R01 · FY2010 · AI · contact PI
Risk Factors and Susceptibility in Gonococcal Infection$384,317
R01 · FY2009 · AI · contact PI
A Meningococcal LOS Vaccine$380,138
R01 · FY2009 · AI · contact PI
A Meningococcal LOS Vaccine$380,138
R01 · FY2008 · AI · contact PI
Risk Factors and Susceptibility in Gonococcal Infection$373,128
R01 · FY2008 · AI · contact PI
A Meningococcal LOS Vaccine$394,000
R01 · FY2007 · AI · contact PI
Risk Factors and Susceptibility in Gonococcal Infection$383,675
R01 · FY2007 · AI · contact PI
IMMUNOCHEMISTRY OF GONOCOCCAL LIPOOLIGOSACCHARIDE$913
P41 · FY2006 · RR · contact PI
A Meningococcal LOS Vaccine$406,000
R01 · FY2005 · AI
IMMUNOCHEMISTRY OF GONOCOCCAL LIPOOLIGOSACCHARIDE$1,697
P41 · FY2005 · RR
A Meningococcal LOS Vaccine$373,600
R01 · FY2004 · AI
IMMUNOCHEMISTRY OF GONOCOCCAL LIPOOLIGOSACCHARIDE$1,392
P41 · FY2004 · RR
IMMUNOCHEMISTRY OF GONOCOCCAL LIPOPOLYSACCHARIDE$291,547
R01 · FY2003 · AI
A Meningococcal LOS Vaccine$186,800
R01 · FY2003 · AI
IMMUNOCHEMISTRY OF GONOCOCCAL LIPOPOLYSACCHARIDE$272,266
R01 · FY2002 · AI
STRUCTURAL STUDIES OF LOS FROM NEISSERIA GONORRHOEAE$0
P41 · FY2002 · RR
IMMUNOCHEMISTRY OF GONOCOCCAL LIPOPOLYSACCHARIDE$263,518
R01 · FY2001 · AI
STRUCTURAL STUDIES OF LOS FROM NEISSERIA GONORRHOEAE$0
P41 · FY2001 · RR
IMMUNOCHEMISTRY OF GONOCOCCAL LIPOPOLYSACCHARIDE$209,732
R01 · FY2000 · AI
IMMUNOCHEMISTRY OF GONOCOCCAL LIPOPOLYSACCHARIDE$45,228
R01 · FY2000 · AI
STRUCTURAL STUDIES OF LOS FROM NEISSERIA GONORRHOEAE$9,880
P41 · FY2000 · RR